ATHE - מחיר למכירות Alterity Therapeutics
The completion of Phase II trials for its Parkinson's disease drug will be the key driver for Alterity Therapeutics (ATHE), with the current metric value standing at 2.20. P/S fluctuations visualize market expectations amid a lack of profitability. Alterity Therapeutics (ATHE) is implementing bioethical principles and minimizing chemical waste. Patient safety is guaranteed by strict temperature control during the transportation of medications to clinics.
פילוחים אנליטיים של חברת Alterity Therapeutics (ATHE)
To diversify my portfolio with high-quality assets, I utilize the valuation of market capitalization relative to annual revenue. This metric measures the cost of one dollar of sales, determining the extent of the premium paid for the business. For Alterity Therapeutics (ATHE), with its exclusive patents for brain degeneration drugs, this calculation reflects market expectations for future R&D success. The current price-to-sales ratio of 2.20 allows for a timely adjustment of the investment strategy.
